Gain Therapeutics

Breaking the Cycle of Inflammation in #Parkinson's Disease https://lnkd.in/es_g27ay

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for #Parkinson’s Disease “The successful completion of the SAD/MAD in 72 healthy subjects with no serious adverse events or discontinuations related to adverse events and the ability to achieve therapeutic plasma levels with oral dosing further confirm our belief in GT-02287’s potential to be a transformative therapy for Parkinson’s disease patients,” commented Gain’s Executive Chairman, Khalid Islam, Ph.D. “We remain on track with our recent guidance and look forward to continuing to advance GT-02287 through clinical development and initiating a trial in Parkinson’s disease patients by Q4 2024.” https://lnkd.in/eyFziRv7

Thank you for the coverage Labiotech.eu and Roohi Mariam Peter. "Clinical candidate gains ground in Parkinson’s trial" American biotech Gain Therapeutics saw promising preclinical results for a Parkinson’s trial recently. Its lead candidate, which is being studied in #Alzheimer’s disease and genetic disorders like #Gaucher disease, was able to slow the progression of #Parkinson’s disease in a mouse model. The drug GT-02287 is an oral protein modulator, which restores the function of an enzyme called #GCase that becomes misfolded due to a gene mutation linked to Parkinson’s disease. By getting the enzyme to function properly, the aggregation of α-synuclein – the hallmark of Parkinson’s – reduces and so does neuroinflammation in the brain. This was reflected in a task given to these mice. The drug was tested to find out the ability of mice to build nests, a task that resembles daily living and requires cognitive thinking. Mice with Parkinson’s who were given the treatment had improved motor function and were able to build nests similar to those without Parkinson’s but nests of those who did not receive treatment were poorly built. The data was presented at the Federation of European Neuroscience Societies - FENS Forum in Austria last week. The drug is now being evaluated in a phase 1 trial and has a good safety and tolerability profile so far. https://lnkd.in/exCStWZw

🚨Breaking news🚨 The Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act was signed into law yesterday! Rep. Wexton, who is living with the diagnosis of PSP, along with her family and that of Rep. Gus Bilirakis, were present to witness President Biden sign this bipartisan legislation that will coordinate federal efforts around the Parkinsonian diseases, including PSP, CBD and MSA. Read her press release here: https://lnkd.in/esgH5_-a This is an incredible and personal victory for our community! Please join us in celebrating this historical moment as well as thanking Rep. Wexton for her tireless work championing this bill and the many hundreds of CurePSP advocates who contacted their members of Congress. Your voice has made — and will continue to make — a difference! Keep checking our social media and www.psp.org/advocacy for further updates as we track the downstream work from this bill. #BecauseHopeMatters #Awareness #PSP #CBD #MSA #NonProfit #Care #Advocacy #Congress #HR2365

Thank you Fierce Pharma and Helen Floersh for your coverage of our recent unveiling of new preclinical data for our GT-02287, at the Federation of European Neuroscience Societies - FENS Forum June 27. “These data further confirm our conviction that GT-02287 can slow or stop progression of #Parkinson’s disease and given the cognitive decline observed in GBA1 Parkinson’s patients, we hope that we can one day deliver this drug to those that need it and help them improve their everyday life,” Joanne Taylor, Ph.D., senior vice president of research at Gain. https://lnkd.in/eX5iywTA

GT-02287 aids motor, cognitive function in GBA1 Parkinson's mice. The Michael J. Fox Foundation for Parkinson's Research The Silverstein Foundation for Parkinson's with GBA https://lnkd.in/ermNsVY3 

This one will get you right in the feels. God Bless Michael J. Fox, one of America's greatest treasures. Thank you for all you've done for the #Parkinson's community Gain Therapeutics received initial funding from The Michael J. Fox Foundation for Parkinson's Research https://lnkd.in/e3N__B8m

Join us 8:30am ET, Monday, July 1, for a Business and Corporate Update hosted by interim-CEO and current CFO Gene Mack. To register early, visit https://lnkd.in/gbvV8hTj A recorded version and transcript of the call will be archived and available for replay in the News and Events section of the Company website within 24 hours after the event.

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies - FENS Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease Data demonstrates improvement in cognitive function in GBA1 hashtag #Parkinson’s disease model in addition to reversal of motor function deficits https://lnkd.in/gnzP6jg2